CS
HRTX icon

Candriam SCA’s Heron Therapeutics HRTX Stock Holding History

Candriam SCA’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-53,993
Closed -$493K – 824
2021
Q4 		$493K Sell
53,993
-112,923
-68% -$1.15M ﹤0.01% 749
2021
Q3 		$1.78M Sell
166,916
-591,654
-78% -$7.2M 0.01% 596
2021
Q2 		$11.8M Sell
758,570
-531,203
-41% -$8.45M 0.08% 263
2021
Q1 		$26.2M Hold
1,289,773
– – 0.22% 122
2020
Q4 		$27.3M Sell
1,289,773
-29,199
-2% -$507K 0.22% 123
2020
Q3 		$19.5M Buy
1,318,972
+40,000
+3% +$624K 0.18% 137
2020
Q2 		$18.8M Buy
1,278,972
+578,462
+83% +$9.5M 0.2% 129
2020
Q1 		$16.1M Hold
700,510
– – 0.18% 131
2019
Q4 		$16.5M Sell
700,510
-306,090
-30% -$6.77M 0.18% 131
2019
Q3 		$18.6M Buy
1,006,600
+338,000
+51% +$6.22M 0.25% 82
2019
Q2 		$12.4M Buy
668,600
+80,000
+14% +$1.6M 0.15% 157
2019
Q1 		$14.4M Buy
588,600
+125,000
+27% +$3.27M 0.18% 124
2018
Q4 		$12M Buy
463,600
+121,200
+35% +$3.33M 0.18% 127
2018
Q3 		$10.8M Buy
342,400
+273,400
+396% +$10.2M 0.14% 177
2018
Q2 		$2.68M Buy
+69,000
New +$2.2M 0.04% 421
2016
Q4 		– Sell
-60,000
Closed -$1.03M – 682
2016
Q3 		$1.03M Buy
+60,000
New +$1.11M 0.02% 488

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Candriam SCA's HRTX Position: Q1 2022 in Review

Candriam SCA sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 53,993 shares — an estimated $493K sold.

Candriam SCA first reported a position in HRTX in Q3 2016 and held it in 16 quarters. The position peaked at $27.3M in Q4 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Candriam SCA reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Candriam SCA sold 53,993 Heron Therapeutics shares in Q1 2022, an estimated $493K.
  • Candriam SCA first reported a position in Heron Therapeutics in Q3 2016 and held it in 16 quarters.
  • Candriam SCA's Heron Therapeutics position peaked at $27.3M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Candriam SCA's 13F filing for Q1 2022, filed 13 May 2022.